Moleculin Biotech, Inc. (NASDAQ:MBRX) went up to recover about 15.8% since recording its record low price of $0.78. The stock experienced -6.25% slump, arriving at $0.9 on 4/12/2019. During the day, the stock price traveled from $0.9 to $0.99. This company shares are 511.11% off its target price of $5.5 and the current market capitalization stands at $26.51M. The recent change has given its price a -27.82% deficit over SMA 50 and -62.96% deficit over its 52-week high. The stock witnessed -26.23% declines, -34.78% declines and -35.25% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MBRX’s volatility during a week at 8.96% and during a month it has been found around 9.05%.

Moleculin Biotech, Inc. (MBRX) Top Holders

Institutional investors currently hold around $1 million or 7.8% in MBRX stock. Look at its top three institutional owners: Vanguard Group Inc owns $619 thousand in Moleculin Biotech, Inc., which represents roughly 2.33% of the company’s market cap and approximately 61.9% of the institutional ownership. Similar statistics are true for the second largest owner, Cibc World Markets Inc., which owns 163,100 shares of the stock are valued at $147 thousand. The third largest holder is Geode Capital Management, Llc, which currently holds $114 thousand worth of this stock and that ownership represents nearly 0.43% of its market capitalization.

Moleculin Biotech, Inc. 13F Filings

At the end of December reporting period, 10 institutional holders increased their position in Moleculin Biotech, Inc. (NASDAQ:MBRX) by some 254,837 shares, 9 decreased positions by 50,440 and 7 held positions by 1,193,808. That puts total institutional holdings at 1,499,085 shares, according to SEC filings. The stock grabbed 4 new institutional investments totaling 98,474 shares while 4 institutional investors sold out their entire positions totaling 25,732 shares.

Moleculin Biotech, Inc. (NASDAQ:MBRX) Insider Trades

Multiple company employees have indulged in significant insider trading. Moleculin Biotech, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Priebe Waldemar has sold 100,000 shares of Moleculin Biotech, Inc. (MBRX) in the trading session dated Aug. 16, 2017. These shares are worth $170,000 and were traded at $1.7 each. The SEC filing shows that KLEMP WALTER V performed a sale of 100,000 shares. The CEO, 10% Owner disposed these shares by way of transaction on Aug. 16, 2017. The company’s shares were given away at $1.7 per share worth to an income of some $170,000 to the account of KLEMP WALTER V.

CEO, 10% Owner, KLEMP WALTER V, purchased 12,000 common shares of Moleculin Biotech, Inc. (MBRX) in the open market. In a transaction dated May. 11, 2017, the shares were bought at an average price of $0.81, giving away a sum of $9,720. After this purchase, 1,067,724 common shares of MBRX are directly owned by the insider, with total stake valued at $960,952.

In the transaction dated May. 05, 2017, a great number of shares acquired came courtesy the Director; Northcut Jacqueline added a total of 1,000 shares at an average price of $0.82, amounting to approximately $820. The insider now directly owns 1,000 shares worth $900.

Moleculin Biotech, Inc. (MBRX) Analyst Guide

Several analysts have released their opinion on Moleculin Biotech, Inc. (NASDAQ:MBRX), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].